155 related articles for article (PubMed ID: 20473320)
1. The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.
Huang R; Chen XQ; Huang Y; Chen N; Zeng H
Asian J Androl; 2010 Jul; 12(4):527-34. PubMed ID: 20473320
[TBL] [Abstract][Full Text] [Related]
2. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
Panka DJ; Wang W; Atkins MB; Mier JW
Cancer Res; 2006 Feb; 66(3):1611-9. PubMed ID: 16452220
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
Oh SJ; Erb HH; Hobisch A; Santer FR; Culig Z
Endocr Relat Cancer; 2012 Jun; 19(3):305-19. PubMed ID: 22383427
[TBL] [Abstract][Full Text] [Related]
5. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
Wei G; Wang M; Carr BI
J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Sinicrope FA
Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
[TBL] [Abstract][Full Text] [Related]
9. Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.
Brüning A; Burger P; Vogel M; Gingelmaier A; Friese K; Burges A
Invest New Drugs; 2010 Oct; 28(5):535-42. PubMed ID: 19554262
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
Fecteau JF; Bharati IS; O'Hayre M; Handel TM; Kipps TJ; Messmer D
Mol Med; 2012 Feb; 18(1):19-28. PubMed ID: 21979753
[TBL] [Abstract][Full Text] [Related]
11. The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.
Brüning A; Rahmeh M; Gingelmaier A; Friese K
Mol Cancer; 2010 Jan; 9():19. PubMed ID: 20105315
[TBL] [Abstract][Full Text] [Related]
12. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.
Kharaziha P; Rodriguez P; Li Q; Rundqvist H; Björklund AC; Augsten M; Ullén A; Egevad L; Wiklund P; Nilsson S; Kroemer G; Grander D; Panaretakis T
Cell Death Dis; 2012 Jan; 3(1):e262. PubMed ID: 22278289
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
Rahmani M; Davis EM; Bauer C; Dent P; Grant S
J Biol Chem; 2005 Oct; 280(42):35217-27. PubMed ID: 16109713
[TBL] [Abstract][Full Text] [Related]
14. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
Roy Choudhury S; Karmakar S; Banik NL; Ray SK
Invest New Drugs; 2010 Dec; 28(6):812-24. PubMed ID: 19777160
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.
Ullén A; Farnebo M; Thyrell L; Mahmoudi S; Kharaziha P; Lennartsson L; Grandér D; Panaretakis T; Nilsson S
Int J Oncol; 2010 Jul; 37(1):15-20. PubMed ID: 20514392
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism.
Chiou JF; Tai CJ; Wang YH; Liu TZ; Jen YM; Shiau CY
Cancer Biol Ther; 2009 Oct; 8(20):1904-13. PubMed ID: 19770576
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S
Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558
[TBL] [Abstract][Full Text] [Related]
19. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.
Rahmani M; Davis EM; Crabtree TR; Habibi JR; Nguyen TK; Dent P; Grant S
Mol Cell Biol; 2007 Aug; 27(15):5499-513. PubMed ID: 17548474
[TBL] [Abstract][Full Text] [Related]
20. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.
Schult C; Dahlhaus M; Ruck S; Sawitzky M; Amoroso F; Lange S; Etro D; Glass A; Fuellen G; Boldt S; Wolkenhauer O; Neri LM; Freund M; Junghanss C
BMC Cancer; 2010 Oct; 10():560. PubMed ID: 20950443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]